Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0GM6E
|
||||
Former ID |
DNCL002637
|
||||
Drug Name |
Pegdinetanib
|
||||
Synonyms |
BMS-844203
|
||||
Indication | Non-small cell lung cancer [ICD10:C33-C34] | Phase 1 | [523078] | ||
Company |
Bristol-Myers Squibb
|
||||
Structure |
Download2D MOL |
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Modulator | [543499] | |
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY network | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.